Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DEDP81
|
|||
| Drug Name |
AMG 910
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Esophagogastric junction neoplasm [ICD-11: 2B71] | Phase 1 | [1] | |
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 1 | [1] | ||
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Claudin-18 (CLDN18) | Target Info | Inhibitor | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Tight junction | ||||
| Leukocyte transendothelial migration | ||||
| Hepatitis C | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Reactome | Tight junction interactions | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04260191) Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Amgen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.